We could not find any results for:
Make sure your spelling is correct or try broadening your search.
G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat most types of cancer, such as cell lung cancer and breast c... G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat most types of cancer, such as cell lung cancer and breast cancer, and designs them to combine - and enhance - the anti-tumor activity of current therapies. Show more
RESEARCH TRIANGLE PARK, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
FALSE000156024100015602412024-02-282024-02-28UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549___________________________FORM 8-K___________________________CURRENT...
- Achieved $46.3 Million in Net Revenue from Sales of COSELAยฎ (trilaciclib) for Full Year 2023, Representing 48% Growth Over 2022; Provided 2024 Net COSELA Revenue Guidance of $60 to $70 Million...
RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1โs Chief Executive Officer Jack...
RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
="/Images/box-unchecked.jpg" alt="Checkbox not checked">2860002/12/2024Cash* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the...
FALSE000156024100015602412024-02-122024-02-12UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549___________________________FORM 8-K___________________________CURRENT...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.96 | 27.8260869565 | 3.45 | 4.765 | 3.45 | 1166397 | 4.15053332 | CS |
4 | 1.21 | 37.8125 | 3.2 | 4.765 | 2.933 | 910232 | 3.68114484 | CS |
12 | 1.46 | 49.4915254237 | 2.95 | 5 | 2.01 | 1480465 | 3.37351388 | CS |
26 | 3.09 | 234.090909091 | 1.32 | 5 | 1.08 | 1313893 | 2.9309293 | CS |
52 | 1.65 | 59.7826086957 | 2.76 | 5 | 1.08 | 1070935 | 2.73382407 | CS |
156 | -17.35 | -79.7334558824 | 21.76 | 26.69 | 1.08 | 1055679 | 8.26879798 | CS |
260 | -10.68 | -70.7753479125 | 15.09 | 41.8 | 1.08 | 902465 | 11.97531664 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions